Hemab to Present Coagulation Program Data at ASH Meeting

The company says initial Phase 2b data for sutacimig in Factor VII deficiency showed multi-fold accumulation of endogenous FVII(a) and shorter prothrombin time after one subcutaneous dose. Preclinical data showed HMB-003 reduced severe menstrual bleeding.